Backed by Big Pharma VCs, Palleon ramps up a new approach to immuno-oncology with a $48M startup round
A couple of years ago, GSK’s venture arm SR One brought in Jim Broderick as its first-ever entrepreneur-in-residence. And today, they’re backing his new cancer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.